We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Lithoplasty System Treats Peripheral Artery Disease

By HospiMedica International staff writers
Posted on 19 Jan 2015
A novel system combines the calcium disrupting power of lithotripsy with the simplicity of a balloon catheter into a single device.

The Lithoplasty system is designed to disrupt and pretreat calcium deposits present in peripheral artery disease (PAD) by applying a brief series of powerful mechanical pulses through the soft tissue. The plaque, having been stressed from the induced vibrations, thus becomes more pliable. The integrated balloon catheter is then dilated at low pressures to expand the lesion evenly without damaging the vessels themselves, minimizing any potential acute soft tissue injury that could lead to the need for additional interventional treatments or long-term restenosis.

Image: The Lithoplasty balloon catheter system (Photo courtesy of Shockwave Medical).
Image: The Lithoplasty balloon catheter system (Photo courtesy of Shockwave Medical).

The balloon dilatation catheter incorporates tiny lithotripsy electrodes that increase the compliance of rigid vascular and valvular lesions prior to the low-pressure dilation. The pretreatment enables more effective angioplasty, less frequent bailout stent usage, and enhanced lesion preparation. In aortic valves, the technology could vastly improve native tissue preparation prior to trans-catheter aortic valve replacement (TAVR) and valvuloplasty for patients not suitable for TAVR. The Lithoplasty system is a product of Shockwave Medical (Fremont, CA, USA), and has received the European Community CE marking of approval.

“CE Mark approval for Lithoplasty in peripheral artery disease is an exciting milestone for Shockwave Medical and sets the stage for regulatory approvals in other geographies,” said Daniel Hawkins, co-founder of Shockwave Medical. “We are also investigating applying this therapy to calcified coronary lesions, another important unmet clinical need.”

“Lithoplasty is a breakthrough that could revolutionize the treatment of peripheral artery disease, a common circulatory problem that can lead to serious complications, including amputation,” said Marianne Brodmann, MD, of the Medical University of Graz (Austria). “With Lithoplasty, even historically very challenging PAD patients with deep calcium can be treated effectively without significant injury to the vessel.”

Related Links:

Shockwave Medical
Medical University of Graz



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Silver Member
Compact 14-Day Uninterrupted Holter ECG
NR-314P
New
Enterprise Imaging & Reporting Solution
Syngo Carbon

Latest Surgical Techniques News

Tiny Wraparound Electronic Implants to Revolutionize Treatment of Spinal Cord Injuries

Small, Implantable Cardiac Pump to Help Children Awaiting Heart Transplant

Gastrointestinal Imaging Capsule a Game-Changer in Esophagus Surveillance and Treatment